Prognostic value of HLA class I expression in patients with oral squamous cell carcinoma

Kazushige Koike1 | Hironari Dehari1 | Shota Shimizu1 | Koyo Nishiyama1 | Tomoko Sonoda2 | Kazuhiro Ogi1 | Junichi Kobayashi1 | Takanori Sasaki1 | Takashi Sasaya1 | Kei Tsuchihashi1 | Tomohide Tsukahara3 | Tadashi Hasegawa4 | Toshihiko Torigoe3 | Hiroyoshi Hiratsuka1 | Akihiro Miyazaki1

1Department of Oral Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan
2Department of Public Health, Sapporo Medical University School of Medicine, Sapporo, Japan
3Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan
4Department of Surgical Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan

Correspondence
Hironari Dehari, Department of Oral Surgery, Sapporo Medical University School of Medicine, South 1 West 16, Chuo-ku, Sapporo 060-8543, Japan.
Email: dehari@sapmed.ac.jp

Abstract
Human leukocyte antigen (HLA) class I molecules play a central role in anticancer immunity, but their prognostic value in oral squamous cell carcinoma (OSCC) remains unclear. We examined HLA class I expression in 2 distinct tumor compartments, namely, the tumor center and invasive front, and evaluated the association between its expression pattern and histopathological status in 137 cases with OSCC. Human leukocyte antigen class I expression was graded semiquantitatively as high, low, and negative. At the invasive front of the tumor, HLA class I expression was high in 72 cases (52.6%), low in 44 cases (32.1%), and negative in 21 cases (15.3%). The HLA class I expression in the tumor center was high in 48 cases (35.0%), low in 58 cases (42.4%), and negative in 31 cases (22.6%). The 5-year overall survival and disease-specific survival rates were good in cases with high HLA class I expression at the invasive front; however, there was no significant difference in survival based on HLA class I expression in the tumor center. In addition, high HLA class I expression was correlated with high CD8+ T cell density, whereas negative HLA class I expression was correlated with low CD8+ T cell density at the invasive front. These results suggest that it is easier for CD8+ T cells to recognize presented peptides in the case of high HLA class I expression at the tumor invasive front and could be a prognostic factor for OSCC.

Keywords
HLA class I, oral squamous cell carcinoma, prognostic factor, survival, tumor-infiltrating lymphocyte

Abbreviations: DSS, disease-specific survival; HLA, human leukocyte antigen; IF, invasive front; IFN-γ, interferon gamma; NK, natural killer; OS, overall survival; OSCC, oral squamous cell carcinoma; RFS, recurrence-free survival; TCE, tumor center.
INTRODUCTION

Oral cancer is the ninth most common malignancy worldwide, with OSCC representing approximately 90% of oral malignancies. Despite advanced knowledge of cancer therapy, more than 145,000 deaths from oral cancer occur annually, with a 5-year survival rate of approximately 50% for OSCC. Unfortunately, this rate has not improved in recent decades, indicating a need for new treatments and therapeutic approaches.

Cancer cells can evade immune surveillance, allowing them to grow and metastasize. One mechanism of immune escape during cancer development is the downregulation of the expression of HLA class I molecules, which are expressed on all nucleated cells and present intracellular protein fragments on the cell surface, particularly for recognition by CTLs, eg, CD8+ T cells. The status of the immune system is an important factor in the prognosis of cancer patients, and HLA class I antigen downregulation has been used as a prognostic biomarker in esophageal cancer, malignant melanoma, lung cancer, ovarian cancer, colon cancer, renal cell carcinoma, and bladder cancer, thus improving the survival of patients. However, the downregulation of HLA class I expression is not observed in all types of cancer, such as gastric cancer. Regardless, the loss of HLA class I molecules has been discussed in the context of tumor aggressiveness, including differentiation, invasiveness, and metastatic potential.

Because most anti-HLA class I Abs recognize the allele-specific native structure of HLA class I molecules, these Abs are unable to react with denatured HLA class I molecules in formalin-fixed paraffin-embedded tissue sections. However, a monoclonal pan-HLA class I Ab, EMR8-5, has been developed that is suitable for immunostaining formalin-fixed tissue specimens. Therefore, we are now able to retrospectively investigate HLA class I expression in surgically resected cancer specimens.

We recently reported that tumor-infiltrating CD8+ T cell density was an independent prognostic marker for OSCC; specifically, CD8+ T cells at the parenchyma of the invasive edge of the tumor were an indicator of recurrence and prognosis. However, there are few reports on HLA class I expression in OSCC, and no study has examined the association between HLA class I expression and CD8+ T cell density in detail. Therefore, in this study, we focused on the expression of HLA class I molecules in cancer cells and its relationship with CD8+ T cell density to investigate its prognostic value in patients with OSCC.

MATERIALS AND METHODS

2.1 Patients and tissue samples

This retrospective study was undertaken according to the principles of the 1964 Declaration of Helsinki and its subsequent revisions and was approved by the Institutional Review Board of our university on 12 September 2017 (No. 292-1116). Informed consent or acceptable substitutes were obtained from all patients before study inclusion. We used tissue samples collected from patients who were diagnosed with OSCC and underwent definitive surgery between January 2004 and December 2014 at Sapporo Medical University Hospital (Table 1). Tissue samples were processed, embedded in paraffin, and sectioned into 4-μm samples. None of the patients received any form of neoadjuvant or adjuvant chemotherapeutic and/or radiotherapy before or after surgery.

2.2 Immunohistochemistry

The monoclonal anti-pan-HLA class I Ab EMR8-5 was established by Torigoe et al. This mouse mAb is commercially available (Hokudo) and reacts with the extracellular domains of HLA-A*2402, A*0101,
A*1101, A*0201, A*0207, B*0801, B*1501, B*3501, B*4001, B*4002, B*4006, B*4403, Cw*0102, Cw*0801, Cw*1202, and Cw*1502. Immunohistochemical staining with EMR8-5 was carried out on formalin-fixed, paraffin-embedded tissue sections after steam heat-induced epitope retrieval. Subsequent incubations with a secondary biotinylated Ab, avidin-conjugated peroxidase complex, and chromogen were undertaken on a Ventana NexES system (Ventana Medical Systems). The slides were counterstained with hematoxylin, rinsed, dehydrated in a graded ethanol series, and coverslipped with mounting media. Positive reactivity to EMR8-5 was confirmed by staining vascular endothelial cells and lymphocytes in sections of tumor specimens. In addition, tissue sections were incubated with a primary mAb against pan-cytokeratin (1:200, clone AE1/AE3; Abcam) to detect multiple cytokeratins and identify tumor cells. CD8\(^+\) T cells were stained according to our previous report.

2.3 | Histopathological and immunohistopathological evaluation

The histological slides were evaluated for lymphovascular invasion, perineural invasion, and histopathological grading. Tumor extent and histopathological grading were classified according to the cancer staging manual of the American Joint Committee on Cancer. Human leukocyte antigen class I expression was evaluated at the TCe and IF at ×200 magnification (Figure 1). For the assessment of HLA class I density in each compartment (ie, TCe and IF), at least 5 fields were viewed, and in heterogeneous cases, the most representative area of the entire section was selected. The HLA class I expression was assessed on a personal computer with DP2-BSW software and an Olympus microscope digital camera by three individuals (authors KK, SS, and HD) (Figure 2). Labels bearing the patient pathology number were covered. Human leukocyte antigen class I expression was classified into 3 categories as previously described\(^\text{25}\): high (more than 50% positive cells), low (5%-50% positive cells), and negative (less than 5% positive cells). Briefly, positivity was defined as complete and homogeneous membrane staining in more than 50% of tumor cells; low positive expression was defined as faint, incomplete, and heterogeneous membrane staining in 5%-50% of tumor cells; and negative expression was defined as membrane staining in less than 5% of tumor cells. CD8\(^+\) T cell expression was also evaluated at the TCe and IF at ×200 magnification (Figure 3). The mean CD8\(^+\) T cell density for each compartment was used to stratify the samples into the high- and low-density groups according to our previous report.\(^\text{19}\)

2.4 | Statistical analysis

Disease-specific survival was calculated from the date of definitive surgery to date of death. Overall survival was defined as the time between the date of definitive surgery and date of death from any cause. Recurrence-free survival was defined as the time between the date of definitive surgery and locoregional or distant tumor recurrence, or death from any cause. Disease-specific survival, OS, and RFS were analyzed using the Kaplan-Meier method and compared using a log-rank test for each group. Variables that had prognostic potential indicated by univariate analysis were evaluated using multivariate analysis with Cox proportional hazard regression models. Associations between HLA class I expression and CD8\(^+\) T cell infiltration density were evaluated using a \(\chi^2\) test. Two-tailed \(P\)-values less than 0.05 were considered statistically significant. SPSS version 23.0 for Windows (IBM) was used for statistical analyses.

3 | RESULTS

3.1 | Patient and tumor characteristics

From January 2004 to December 2014, a total of 221 patients with primary OSCC were treated by curative surgery. Of these, 137 patients were treated without neoadjuvant or adjuvant therapy, and sufficient tissue samples from these patients were available for further analysis. The 137 patients with OSCC comprised 76 men (55.5%) and 61 women (44.5%) with a median age of 68 (range, 33-93) years at first presentation. Anatomical sites included the tongue/floor of the mouth (89 tumors, 65.0%) and other regions of the oral cavity (48 tumors, 35.0%). Using the UICC staging classification system, the participants were classified as follows: 42 patients in
stage I (30.7%), 61 in stage II (44.5%), and 34 in stage III/IV (24.8%). Histopathological grading was as follows: 73 patients were assigned grade 1 (53.3%), 59 were assigned grade 2 (43.1%), and 5 were assigned grade 3 (3.6%). One hundred and fifteen patients (83.9%) did not have lymphovascular invasion, whereas it was present in 22 patients (16.1%); 125 patients (91.2%) did not have perineural invasion, but it was present in 12 patients (8.8%).

3.2 | Relationship between clinicopathological data and survival rates

The median follow-up period for all patients was 79 (range, 4-164) months. Primary tumors recurred in 16 patients (11.6%), and regional lymph node relapse was observed in 24 patients (17.5%). Five-year DSS, OS, and RFS rates for all patients were 90.5%, 83.2%, and 62.8%, respectively (Table 2). Age and perineural invasion were associated with DSS, OS, and RFS and thus considered important indicators.

5 | Relationship between HLA class I expression and survival rates

Expression of HLA class I was measured in the OSCC sections to evaluate different tumor regions. At the IF, 72 cases (52.6%) had high HLA class I expression, 44 (32.1%) had low expression, and 21 (15.3%) were negative. At the TCe, 48 cases (35.0%) had high HLA class I expression, 58 (42.4%) had low expression, and 31 (22.6%) were negative. These results indicated that HLA class I molecules are expressed differentially in different compartments of OSCC.
KOIKE ET AL.

TABLE 2 Five-year overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS) according to clinicopathological variables in patients with oral squamous cell carcinoma

| Observed findings                  | OS      | Log-rank test (P value) | DSS      | Log-rank test (P value) | RFS      | Log-rank test (P value) |
|------------------------------------|---------|-------------------------|----------|-------------------------|----------|-------------------------|
|                                    | Survival rate (%) |                        | Survival rate (%) |                        | Survival rate (%) |                        |
| Sex                                |          |                        |          |                        |          |                        |
| Male                               | 82.9    | 0.930                   | 90.8     | 0.890                   | 65.8     | 0.340                   |
| Female                             | 83.6    |                        | 90.2     |                        | 59.0     |                        |
| Age, y                             |          |                        |          |                        |          |                        |
| <68                                | 95.2    | **0.001**               | 98.4     | **0.003**               | 74.6     | **0.010**               |
| ≥68                                | 73.0    |                        | 83.8     |                        | 52.7     |                        |
| Anatomical site                    |          |                        |          |                        |          |                        |
| Tongue/floor of the mouth          | 88.8    | **0.009**               | 94.4     | **0.020**               | 66.3     | 0.160                   |
| Other                              | 72.9    |                        | 83.3     |                        | 56.3     |                        |
| Primary tumor                      |          |                        |          |                        |          |                        |
| T1                                 | 95.7    | **0.001**               | 97.8     | **0.030**               | 69.6     | 0.120                   |
| T2                                 | 80.5    |                         | 88.3     |                         | 62.3     |                         |
| T3/4                               | 57.1    |                         | 78.6     |                         | 42.9     |                         |
| Regional lymph nodes               |          |                        |          |                        |          |                        |
| N (−)                              | 88.0    | **0.001**               | 95.4     | **<0.001**              | 65.7     | 0.170                   |
| N (+)                              | 65.5    |                         | 72.4     |                         | 51.7     |                         |
| Stage grouping                     |          |                        |          |                        |          |                        |
| Stage I                            | 97.6    | **<0.001**              | 100.0    | **0.001**               | 71.4     | 0.140                   |
| Stage II                           | 83.6    |                         | 91.8     |                         | 63.9     |                         |
| Stage III/IV                       | 64.7    |                         | 76.5     |                         | 50.0     |                         |
| Histopathological grading          |          |                        |          |                        |          |                        |
| Grade 1                            | 87.7    | 0.330                   | 94.5     | 0.210                   | 71.2     | **0.003**               |
| Grade 2                            | 78.0    |                         | 86.4     |                         | 55.9     |                         |
| Grade 3                            | 80.0    |                         | 80.0     |                         | 20.0     |                         |
| Lymphovascular invasion            |          |                        |          |                        |          |                        |
| Absent                             | 86.1    | 0.050                   | 92.2     | 0.140                   | 67.0     | **0.010**               |
| Present                            | 68.2    |                         | 81.8     |                         | 40.9     |                         |
| Perineural invasion                |          |                        |          |                        |          |                        |
| Absent                             | 86.4    | **<0.001**              | 92.8     | **0.001**               | 66.4     | **0.001**               |
| Present                            | 50.0    |                         | 66.7     |                         | 25.0     |                         |

Two-tailed P-values less than 0.05 were considered statistically significant.

high HLA class I expression at the IF compared with patients with low and negative expression (P = 0.04), whereas there was no significant difference in DSS according to HLA class I expression in the TCe (Figure 5). Recurrence-free survival was not significantly different among all patients (Figure 6). Together, these results indicated that HLA class I expression at the IF could be a prognostic factor for OS and DSS in patients with OSCC.

In multivariate analysis, HLA class I expression at the IF was an independent prognostic factor for OS (hazard ratio 0.43; 95% confidence interval, 0.20-0.91; P = 0.02). Age, stage grouping, and perineural invasion were independent prognostic factors for RFS. Overall, these results suggested that HLA class I expression at the IF could be a prognostic factor for OS (Table 3).

6 | Relationship between HLA class I expression and CD8+ T cell density

At the IF, high HLA class I expression was correlated with high CD8+ T cell density. In addition, negative HLA class I expression was correlated with low CD8+ T cell density. In contrast, there was no significant difference in the TCe (Table 4). These results suggested that it is easier for CD8+ T cells
to recognize presented peptides in the case of high HLA class I expression at the IF, whereas the ability of CD8⁺ T cells to recognize presented peptides in the case of low HLA class I expression is impaired.

**7 | DISCUSSION**

There are several clinical and pathological prognostic factors for cancer, but only a few immunological prognostic methods. The immunological state of the host can influence the prognosis and features of cancer. Human leukocyte antigen class I molecules play a central role in cell-mediated immunity, especially as antigen-presenting molecules for CTLs, which recognize tumor antigen-bound peptides presented on the cell surface through HLA class I molecules and kill the target cancer cell. Human leukocyte antigen class I expression appears to be lost or downregulated on the tumor cell surface, which could represent a mechanism for neoplastic cells to escape killing by CTLs, allowing tumor dissemination and metastasis. The total loss of HLA class I expression reportedly occurs in approximately 15% and 40% of primary and metastatic head and neck SCC lesions.
respectively. Similarly, in our study, the loss of HLA class I expression at the IF was observed in 15% (21/137) of cases.

Recent reports have shed light on the immunological tumor microenvironment and immune escape mechanisms of cancer cells,
but a detailed understanding is still lacking. The clinical relevance of the immunological tumor microenvironment, including the prognostic value of CD8⁺ T cells, is controversial and remains to be elucidated.

In addition, the prognostic value of the spatial heterogeneity (IF vs TCe) of tumor-infiltrating lymphocytes and immune escape mechanisms remains unclear.

Therefore, we focused on the expression of HLA class I molecules to identify possible novel immunological prognostic factors. Our data showed that high HLA class I expression at the IF of OSCC was significantly related to better OS and DSS compared with low or negative HLA class I expression, which was consistent with the findings of other studies and suggests that the level of HLA class I expression at the IF could be a prognostic factor. Because HLA class I expression at the IF was associated with decreased cancer cell proliferation and metastasis based on survival, it might exert a protective effect against cancer. In addition, we previously reported that CD8⁺ T cell density at the IF was an indicator of tumor recurrence and prognosis.

The cases analyzed in our previous and present studies largely overlapped, but in the present study, we analyzed the relationship between CD8⁺ T cell density and HLA class I expression. Negative HLA class I expression was correlated with low levels of CD8⁺ T cells at the IF, but there was no significant difference in the TCe. It is possible that CD8⁺ T cells were concentrated at the IF because tumor vasculature was enriched in the infiltrative margin, but not in the tumor center. In addition, we found that CD8⁺ T cells were not recruited to sites where HLA class I expression was downregulated.

Therefore, we focused on the expression of HLA class I molecules to identify possible novel immunological prognostic factors. Our data showed that high HLA class I expression at the IF of OSCC was significantly related to better OS and DSS compared with low or negative HLA class I expression, which was consistent with the findings of other studies and suggests that the level of HLA class I expression at the IF could be a prognostic factor. Because HLA class I expression at the IF was associated with decreased cancer cell proliferation and metastasis based on survival, it might exert a protective effect against cancer. In addition, we previously reported that CD8⁺ T cell density at the IF was an indicator of tumor recurrence and prognosis.

The cases analyzed in our previous and present studies largely overlapped, but in the present study, we analyzed the relationship between CD8⁺ T cell density and HLA class I expression. Negative HLA class I expression was correlated with low levels of CD8⁺ T cells at the IF, but there was no significant difference in the TCe. It is possible that CD8⁺ T cells were concentrated at the IF because tumor vasculature was enriched in the infiltrative margin, but not in the tumor center. In addition, we found that CD8⁺ T cells were not recruited to sites where HLA class I expression was downregulated.

Tsukahara et al reported that patients with osteosarcoma who had high HLA class I expression had significantly better OS and disease-free survival than those with HLA class I-negative osteosarcoma. Most reports, including the present study, suggest that the downregulation of HLA class I expression is associated with poor prognosis. In contrast, Maddj et al reported that the total loss of HLA class I expression was an independent indicator of good prognosis in breast cancer. They considered that the loss of HLA class I expression at the IF was an indicator of tumor recurrence and prognosis.

### Table 3: Multivariate analysis of overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS) in patients with oral squamous cell carcinoma

| Parameters                  | OS       |          |          | DSS      |          |          | RFS      |          |          |
|-----------------------------|----------|----------|----------|----------|----------|----------|----------|----------|----------|
|                            | HR 95% CI| P value  |          | HR 95% CI| P value  |          | HR 95% CI| P value  |          |
| Immunohistochemical findings|          |          |          |          |          |          |          |          |          |
| TCe                         | 0.56     | 0.26-1.18| 0.13     | 0.13     | 0.01-1.02| 0.05     | 0.81     | 0.50-1.31| 0.40     |
| IF                          | 0.43     | 0.20-0.91| 0.02     | 0.38     | 0.11-1.26| 0.11     | 0.80     | 0.52-1.24| 0.32     |
| Clinical findings           |          |          |          |          |          |          |          |          |          |
| Sex                         | 0.53     | 0.21-1.31| 0.17     | 0.64     | 0.17-2.28| 0.48     | 1.17     | 0.66-2.07| 0.59     |
| Age                         | 5.13     | 1.35-19.37| 0.01    | 28.00    | 1.48-529.22| 0.02    | 1.74     | 0.89-3.42| 0.10     |
| Anatomical site             | 1.92     | 0.64-5.74| 0.24     | 1.49     | 0.25-8.89| 0.65     | 1.18     | 0.58-2.38| 0.63     |
| Primary tumor               | 1.63     | 0.64-4.16| 0.30     | 1.49     | 0.37-3.87| 0.76     | 1.11     | 0.54-2.30| 0.76     |
| Stage grouping              | 2.82     | 1.20-6.64| 0.01     | 7.74     | 1.43-41.89| 0.01    | 1.16     | 0.64-2.12| 0.61     |
| Pathological findings       |          |          |          |          |          |          |          |          |          |
| Histopathological grading   | 1.08     | 0.49-2.34| 0.84     | 1.31     | 0.40-4.21| 0.64     | 1.53     | 0.90-2.59| 0.11     |
| Lymphovascular invasion     | 2.49     | 0.92-6.69| 0.07     | 3.77     | 0.68-14.82| 0.13    | 1.62     | 0.82-3.20| 0.16     |
| Perineural invasion         | 3.58     | 1.15-11.13| 0.02    | 6.85     | 1.12-41.75| 0.03    | 2.02     | 0.87-4.68| 0.09     |

Two-tailed P-values less than 0.05 were considered statistically significant.

### Table 4: Relationship between human leukocyte antigen (HLA) class I expression and infiltrating CD8⁺ T cell density in patients with oral squamous cell carcinoma

| Number of cases with CD8⁺ T cell density | Low, n (%) | High, n (%) | P value |
|-----------------------------------------|------------|-------------|--------|
| HLA class I expression                  |            |             |        |
| IF                                      | 17 (81.0)  | 4 (19.0)    | 0.003  |
| Low (n = 44)                            | 31 (70.5)  | 13 (29.5)   |        |
| High (n = 72)                           | 33 (45.8)  | 39 (54.2)   |        |
| TCe                                     |            |             |        |
| Negative (n = 31)                       | 23 (74.2)  | 8 (25.8)    | 0.050  |
| Low (n = 58)                            | 28 (48.3)  | 30 (51.7)   |        |
| High (n = 48)                           | 25 (52.1)  | 23 (47.9)   |        |

Two-tailed P-values less than 0.05 were considered statistically significant.

Abbreviations: CI, confidence interval; HR, hazard ratio; IF, invasive front; TCe, tumor center.
molecules could make tumors more susceptible to NK cells and result in a better prognostic outcome due to the presence of HLA class I allele-specific killer cell inhibitory receptors on the surface of NK cells. Thus, in the absence of HLA class I expression, specific killer cell inhibitory receptor-mediated inhibitory signaling is lost and NK cytolytic effector functions are activated. Natural killer cell-mediated cytotoxicity is regulated by a delicate balance between activating and inhibitory signals. Therefore, the prognostic influence of HLA class I expression might depend on the status of cancer immunity.

We observed a few cases in which HLA class I expression and CD8⁺ T cell density were not correlated, but this could be explained by the presence of IFN-γ, which is a central cytokine that coordinates tumor immune responses and the associated biological consequences. In fact, detection of IFN-γ mRNA expression at the IF has been reported in tumor cells and immune cells in OSCC. In the present study, we confirmed CD4⁺ T cell infiltration at the IF (Figure S1). Because IFN-γ is secreted mainly by activated CD4⁺ T cells, we considered that this IFN-γ might be responsible for the up-regulation of HLA class I molecules.

Many studies on HLA class I expression in cancer have produced contradictory results, perhaps due to the use of highly heterogeneous populations and because the distribution of HLA alleles and the linkage disequilibrium among alleles of diverse HLA genes differ in various ethnic populations. In addition, relatively small populations were included in several studies, and the Abs, immunostaining methods, and scoring systems differed. Finally, the cut-off used to classify downregulation and HLA class I-positive groups varied substantially. Due to the differences in these criteria, a reliable comparison of these studies is difficult to carry out.

Our study showed a survival benefit for patients expressing HLA class I molecules, suggesting that the class I-restricted CTL pathway plays a major role in immune surveillance in patients with OSCC. Due to the small sample size of the present analysis, larger studies need to be undertaken to verify the significance of HLA class I expression in prognosis and the applicability of T cell-based immunotherapy for patients with OSCC.

DISCLOSURE
The authors have no conflicts of interest to disclose.

ORCID
Kazushige Koike https://orcid.org/0000-0001-6880-2454
Tomohide Tsukahara https://orcid.org/0000-0002-3678-4359
Akihiro Miyazaki https://orcid.org/0000-0003-3290-6205

REFERENCES
1. Roser M, Ritchie H. Cancer. OurWorldinData.org. 2015. https://ourworldindata.org/cancer. Accessed December 6, 2019.
2. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45:309-316.
3. Marincola FM, Jaffee EM, Hicklin DJ, et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol. 2000;74:181-273.
4. Seliger B, Cabrera T, Garrido F, et al. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol. 2002;12:3-13.
5. Raffaghello L, Prigione I, Airoldi I, et al. Mechanisms of immune evasion of human neuroblastoma. Cancer Lett. 2005;228:155-161.
6. Lopez-Albaitero A, Nayak JV, Ogino T, et al. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol. 2006;176:3402-3409.
7. Boxberg M, Leising L, Steiger K, et al. Composition and clinical impact of the immunologic tumor microenvironment in oral squamous cell carcinoma. J Immunol. 2018;202:278-291.
8. Hosch SB, Izbricki JR, Pichlmeyer U, et al. Expression and prognostic significance of immunoregulatory molecules in esophageal cancer. Int J Cancer. 1997;74:582-587.
9. Kageshita T, Hirai S, Ono T, et al. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol. 1999;154:745-754.
10. Kikuchi E, Yamazaki K, Torigoe T, et al. HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci. 2007;98:1424-1430.
11. Vitale M, Pelusi G, Taroni B, et al. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin Cancer Res. 2005;11:67-72.
12. Watson NF, Ramage JM, Madjid Z, et al. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer. 2006;118:6-10.
13. Kitamura H, Honma I, Torigoe T, et al. Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal cell carcinoma. J Urol. 2007;177:1269-1272.
14. Homma I, Kitamura H, Torigoe T, et al. Human leukocyte antigen class I down-regulation in muscle-invasive bladder cancer: its association with clinical characteristics and survival after cystectomy. Cancer Sci. 2009;100:2331-2334.
15. Lee WH, Min SK, Ju YS, et al. Prognostic significance of HLA class I expression in gastric carcinoma defined by monoclonal anti-pan HLA class I antibody, EMR8-5. J Gastrointest Surg. 2011;15:1336-1343.
16. Mizukami Y, Kono K, Maruyama T, et al. Downregulation of HLA class I molecules in the tumor is associated with a poor prognosis in patients with esophageal squamous cell carcinoma. Br J Cancer. 2008;99:1462-1467.
17. Kaneko K, Ishigami S, Kijima Y, et al. Clinical implication of HLA class I expression in breast cancer. BMC Cancer. 2011;11:454.
18. Torigoe T, Asanuma H, Nakazawa E, et al. Establishment of a monoclonal anti-pan HLA class I antibody suitable for immunostaining of formalin-fixed tissue: unusually high frequency of down-regulation in breast cancer tissues. Pathol Int. 2012;62:303-308.
19. Shimizu S, Hiratsuka H, Koike K, et al. Tumor-infiltrating CD8⁺ T-cell density is an independent prognostic marker for oral squamous cell carcinoma. Cancer Med. 2019;8:80-93.
20. Abbas AK, Lichtman AH. Basic Immunology: Functions and Disorders of the Immune System, 3rd edn. Philadelphia, PA: Saunders/Elsevier; 2009.
21. Tanq Q, Zhang J, Qi B, et al. Downregulation of HLA class I molecules in primary oral squamous cell carcinomas and cell lines. Arch Med Res. 2009;40:256-263.
22. Tsukahara T, Kawaguchi S, Torigoe T, et al. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci. 2006;97:1374-1380.
23. Le Neel T, Moreau A, Laboisse C, et al. Comparative evaluation of automated systems in immunohistochemistry. Clin Chim Acta. 1998;278:185-192.
24. Amin MB, Edge SB, Greene FL, et al. *American Joint Committee on Cancer Staging Manual*, 8th edn. New York, NY: Springer; 2017.
25. Al-Batran SE, Rafiyan MR, Atmaca A, et al. Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma. *Cancer Res.* 2005;65:3937-3941.
26. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. *Nat Immunol.* 2002;3:999-1005.
27. Bubenik J. MHC class I down-regulation: tumor escape from immune surveillance? *Int J Oncol.* 2004;25:487-491.
28. Pistillo MP, Nicolò G, Salvi S, et al. Biochemical analysis of HLA class I subunits expression in breast cancer tissues. *Hum Immunol.* 2000;61:397-407.
29. Ferris RL, Hunt JL, Ferrone S. Human leukocyte antigen (HLA) class I defects in head and neck cancer. *Immune Res.* 2005;2:113-133.
30. Liu S, Liu D, Li J, et al. Regulatory T cells in oral squamous cell carcinoma. *J Oral Pathol Med.* 2016;45:635-639.
31. Lei Y, Xie Y, Tan YS, et al. Telltale tumor infiltrating lymphocytes (TIL) in oral, head & neck cancer. *Oral Oncol.* 2016;61:159-165.
32. Straub M, Drecoll E, Pfarr N, et al. CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity. *Oncotarget.* 2016;7:12024-12034.
33. Lechner A, Slößer H, Rothschild SI, et al. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma. *Oncotarget.* 2017;8:44418-44433.
34. Wang S, Sun M, Gu C, et al. Expression of CD163, interleukin-10, and interferon-gamma in oral squamous cell carcinoma: mutual relationships and prognostic implications. *Eur J Oral Sci.* 2014;122:202-209.
35. Russell S, Angell T, Lechner M, et al. Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma. *Head Neck Oncol.* 2013;5:24.
36. Chen WY, Wu CT, Wang CW, et al. Prognostic significance of tumor-infiltrating lymphocytes in patients with operable tongue cancer. *Radiat Oncol.* 2018;13:157.
37. Fridman WH, Pagès F, Sautès-Fridman C, et al. The immune contexture in human tumours: impact on clinical outcome. *Nat Rev Cancer.* 2012;12:298-306.
38. Madjd Z, Spendlove I, Pinder SE, et al. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. *Int J Cancer.* 2005;117:248-255.
39. Parker BS, Rautela J, Hertzog PJ. Antitumour actions of interferons: implications for cancer therapy. *Nat Rev Cancer.* 2016;16(3):131-144.
40. Duluc D, Corvaisier M, Blanchard S, et al. Interferon-γ reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. *Int J Cancer.* 2009;125:367-373.
41. Lee HW, Hahn KB, Lee JS, et al. Association of HLA class II alleles with chronic atrophic gastritis and gastric carcinoma. *J Dig Dis.* 2009;10:265-271.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

**How to cite this article:** Koike K, Dehari H, Shimizu S, et al. Prognostic value of HLA class I expression in patients with oral squamous cell carcinoma. *Cancer Sci.* 2020;111:1491-1499. [https://doi.org/10.1111/cas.14388](https://doi.org/10.1111/cas.14388)